(Q42994524)

12 November 2017

title

Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy (English)

1 reference

12 November 2017

1 reference

1 reference

Jean-Michel Pawlotsky

2

1 reference

12 November 2017

10

1 reference

12 November 2017

R Gish

9

0 references

Norah A Terrault

1

object named as

N A Terrault

1 reference

12 November 2017

J McHutchison

3

1 reference

12 November 2017

F Anderson

4

1 reference

12 November 2017

M Krajden

5

1 reference

12 November 2017

S Gordon

6

1 reference

12 November 2017

I Zitron

7

1 reference

12 November 2017

R Perrillo

8

1 reference

12 November 2017

M Friesenhahn

11

1 reference

12 November 2017

language of work or name

1 reference

1 September 2005

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

12

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

465-472

1 reference

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Monitoring of viral levels during therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00615.X

10.1111/J.1365-2893.2005.00615.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference